Best Master’s Degrees in Biotechnology 2016

Campus Full time Part time 3-6semesters September 2016 USA New York City + 1 more

The Master of Science in Bioethics, part of Columbia Universitys Programs in Bioethics, which also include an Online Certification of Professional Achievement and Online Noncredit Courses, grounds students in historical, philosophical, legal, and social-scientific approaches and models to address bioethical challenges. [+]

Masters in Biotechnology. Issues concerning the ethical, legal, and social implications of advances in biotechnology and biomedicine are increasingly arising both in the United States and abroad. From stem cell research to healthcare reform, these topics involve critical dilemmas at the intersections of law, society, culture, public policy, philosophy, religion, economics, and history. Scientists, healthcare providers, and policy-makers confront how to approach these complex questions, yet scientific and technological advances have far outpaced our ability to understand or make key decisions about these issues. The Master of Science in Bioethics, part of Columbia Universitys Programs in Bioethics, which also include an Online Certification of Professional Achievement and Online Noncredit Courses, grounds students in historical, philosophical, legal, and social-scientific approaches and models to address bioethical challenges. The program prepares students to work in various capacities within this new and ever-growing field, and includes a concentration in global bioethics the first of its kind in the United States. Students can study with faculty from across the University and draw on the extraordinary resources of the College of Physicians and Surgeons, the Mailman School of Public Health, the schools of Law, Journalism, Nursing and International and Public Affairs, and the Arts and Sciences. Curriculum 36 points for degree completion On-campus instruction; some courses available online Part-time* or Full-time program Fall intake only 3-6 terms to complete** Masters Thesis * Enrollment in the part-time option of this program does not meet the full-time requirements for an F1 student visa. ** Three years maximum. The 36-point program is composed of six core courses, five electives chosen from the University course offerings, and a masters thesis. Students are assigned to a primary faculty advisor, with whom they work closely to design an individualized program that best meets their needs. Students may then focus, if they choose, on one of a variety of areas, including clinical ethics, research ethics, neuroethics, reproductive ethics, environmental ethics, or other realms. It is recommended that students take the core courses in a specific order - the Philosophy of Bioethics and the History of Bioethics should be taken before the other cores (or concurrently with Clinical Bioethics). Global Bioethics should be taken after the Philosophy of Bioethics, the History of Bioethics and Clinical Bioethics. Additional course work includes five electives chosen from the University course offerings (one in law or policy, one in ethics, and one in social science methods). Students are also strongly encouraged to take one in genetics and, depending on their interest, one in environmental science. These electives may be taken at any time. Students are required to complete a thesis, working closely with one of the program's core and/or affiliated faculty members, due in the student's final semester. Thesis assignments are based, as much as possible, on the student's main areas of interest within bioethics and are intended to be a serious independent work of scholarship. Topics are chosen in close consultation with the students core faculty advisor, or with members of the Advisory Board and faculty affiliates. The M.S. in Bioethics is offered on both a full and part-time basis, but either option demands a serious commitment of time and energy. Students are expected to devote significant time to completing reading and class assignments, and papers outside of class. Students may hold a full-time job simultaneously, but should bear in mind the significant demands of the program. Depending on the individual course of study, students may complete the program in one academic year or in a maximum of three years, if the program is done on a part-time basis. Of the six core courses, three are offered each fall and three are offered each spring. The core courses are not offered during the summer, but students may take electives during that time. During the academic year, core courses meet once a week on weekdays from 4:10 to 6 p.m. or evenings from 6:10 to 8 p.m. Elective courses vary depending on the semester. Students should expect to spend an average of eight hours per week on readings, or attendance at outside meetings (e.g. hospital ethics committee meetings) for each core class. The number of hours that the masters thesis will require varies widely, depending on the student, and the specific project. Some projects may entail collection of data, while others may rely on scholarly sources, and the time estimates of each of these may vary depending in part on the difficulty of locating appropriate sources. In order to receive the master's degree in Bioethics, students must complete all requirements for the degree with an overall grade point average of 3.0 (B) or better. [-]

Continue reading here:
Best Master's Degrees in Biotechnology 2016

Everbridge Customer Perspective: A Major Biotechnology Corporation – Video


Everbridge Customer Perspective: A Major Biotechnology Corporation
Gordon Boughtin, Principal Business Continuity Manager at a Major Biotechnology Corporation, discusses how the Everbridge system is utilized during disruptive events, such as earthquakes and...

By: Everbridge

View original post here:
Everbridge Customer Perspective: A Major Biotechnology Corporation - Video

Nigeria Biotechnology Development Agency Workshop on diagnosis and treatment options of Ebola – Video


Nigeria Biotechnology Development Agency Workshop on diagnosis and treatment options of Ebola
Salihu Abdullahi Nigerian scientists have been challenged to come up with treatment options against the Ebola virus disease. The Minister of Science and Technology Dr. Abdul Bulama gave the...

By: NTANews

Read the original:
Nigeria Biotechnology Development Agency Workshop on diagnosis and treatment options of Ebola - Video

| Corporate | Arcturus Bio Cloud – The Future of BioTechnology (Singularity University) – Video


| Corporate | Arcturus Bio Cloud - The Future of BioTechnology (Singularity University)
Inspired by the Dollar Shave Club. JMarcMedia Production - SF Bay Area http://www.jmarcmedia.com We #39;re on Yelp! http://goo.gl/oKE87i Corporate | Promotional | Shot Film Check out our latest film...

By: jmarcmedia

Read the rest here:
| Corporate | Arcturus Bio Cloud - The Future of BioTechnology (Singularity University) - Video

Interview with Caroline Strain – Scotland’s national plan for industry biotechnology – Video


Interview with Caroline Strain - Scotland #39;s national plan for industry biotechnology
Scottish Enterprise #39;s Nation Manager for Chemicals, Caroline Strain, talks about Scotland #39;s national plan for industrial biotechnology. The plan is to be rolled out under four themes: Skills...

By: Scottish Enterprise

Link:
Interview with Caroline Strain - Scotland's national plan for industry biotechnology - Video

The Story of Rainbow Papaya – Why Public Sector Biotechnology Research Matters – Video


The Story of Rainbow Papaya - Why Public Sector Biotechnology Research Matters
Dennis Gonsalves is a former Liberty Hyde Bailey Professor of Plant Pathology at Cornell University. He speaks about the story of Rainbow Papaya as an example of how public sector biotechnology...

By: The Cornell Alliance for Science

The rest is here:
The Story of Rainbow Papaya - Why Public Sector Biotechnology Research Matters - Video

Citrus Greening Disease – Can Biotechnology Help Save Citrus? – Video


Citrus Greening Disease - Can Biotechnology Help Save Citrus?
Ricke Kress is the President of Southern Gardens Citrus. He talks about a new disease that is ravaging citrus operations in Florida and how biotechnology may be able to save our citrus.

By: The Cornell Alliance for Science

See the original post:
Citrus Greening Disease - Can Biotechnology Help Save Citrus? - Video

Biotechnology | Amrita Vishwa Vidyapeetham (Amrita University)

Amrita School of Biotechnology, with qualified faculty including several Ph. D.s recruited from academia and industry around the world, is perfectly poised to offer students an opportunity to develop expertise and succeed in building a career in the exciting areas of biotechnology and related fields. Our cutting-edge curricula with state-of-the-art facilities for teaching and research will provide a solid foundation in the biological sciences. With a vibrant academic environment and a unique approach to learning that involves thought-provoking discussions and constant interaction among students and faculty,...Read More

The School offers three postgraduate and two undergraduate programs in biotechnology, microbiology and bioinformatics as well as research programs.Read more

The faculty, well-known and highly respected in their respective academic fraternities, is really what distinguishes School of Biotechnology. They are drawn from among the best minds in the world. This affords the school an extensive network of contacts which are instrumental in getting collaborative researches, live student projects and industry inputs so essential to quality biotechnology education. The faculty includes acclaimed scholars and award winning professors drawn from all life sciences disciplines. The eclectic blend of faculty, academicians, researchers, and professionals drawn from India and abroad...Read more

Over the years Amrita School of Biotechnology has developed working relationships with many of the best universities in the world. Strong collaboration with national and international organizations is the hallmark of all research carried out at Amrita School of Biotechnology and to this extent we have developed a broad range of international partnerships around the world. We, at Amrita, give tremendous significance to research and development of new products and technologies and with more than a hundred research projects aiming to benefit society...Read more

The School of Biotechnology is nestled in a serene campus located adjacent to the scenic backwaters of Kerala and the Arabian Sea. Despite the rigors of a life devoted to excellence in technology, creativity blossoms naturally and the spirit of selfless service adds fragrance to every event. The School has separate boarding and mess facilities... Read more

Read this article:
Biotechnology | Amrita Vishwa Vidyapeetham (Amrita University)

The Minneapolis Medical Research Foundation Selects Goodwin … – PR Newswire (press release)

"For over 15 years, Goodwin Biotechnology has been one of the pioneers in providing development services and GMP manufacturing of a broad portfolio of Antibody:Drug Conjugate (ADC) and Protein:Drug Conjugate (PDC) projects, including cytotoxic ADCs, Radio-Immunoconjugates, Antibody:Peptide Conjugates, Antibody:Dye Conjugates, PEGylated proteins, and other bioconjugates including Biobetters," said Muctarr Sesay, Ph.D., Chief Scientific Officer at Goodwin Biotechnology. "Our experience in Bioconjugation has resulted in several patents and publications, as well as proprietary processes that enable us to help our clients overcome some significant challenges in developing their next generation of bioconjugates. When including our experience in manufacturing vaccines for use in early- and late-stage clinical trials, we found the Minneapolis Medical Research Foundation project to be highly intriguing."

"This is not an unusual approach for us when we initiate a project because we collaborate with many of our clients in the early stages of proof of concept/development by empirically recommending the appropriate processes to create a viable ADC or PDC candidate," Dr. Sesay continued. "We then blend that with a solutions-oriented approach to help our clients overcome significant challenges to ensure that the process for their candidate is robust, compliant, economical, and scalable."

"We are proud to help advance the treatment for this growing public health concern because we're confident in the expertise that our highly skilled scientists have developed in the areas of ADCs and PDCs, based on the successful work that we have done with over 400 client projects over the last 24 plus years," said Karl Pinto, Chief Executive Officer at Goodwin Biotechnology, Inc. "Our Bioconjugation capabilities complement our experience in successfully developing and manufacturing monoclonal antibodies, recombinant proteins, and vaccines through mammalian cell culture expression systems. So, as part of our Single Source Solution, Goodwin is uniquely qualified to partner with our clients to meet their needs by developing customized and flexible approaches for manufacturing antibodies and recombinant proteins, for example, and / or design the appropriate conjugation activities to cost effectively deliver their product candidates on time."

About the Minneapolis Medical Research Foundation

The Minneapolis Medical Research Foundation (MMRF) is a subsidiary of Hennepin Healthcare System, Inc., and operates as the research arm of Hennepin County Medical Center, an acute care research and teaching hospital in Minneapolis. MMRF is one of the largest nonprofit medical research organizations in Minnesota and consistently ranks in the top 10 percent of all institutions receiving research funding from the National Institutes of Health. To learn more, visit mmrf.org.

About Goodwin Biotechnology, Inc.

Goodwin Biotechnology is a uniquely qualified CDMO that offers a Single Source Solution for our clients from cell line development (through our strategic partner), exploratory proof of concept projects through process development and cGMP contract manufacturing of monoclonal antibodies, recombinant proteins, vaccines, and Biologic Drug Conjugates including Antibody:Drug Conjugates (ADCs) for early and late stage clinical trials. By working with Goodwin Biotechnology, clients can enhance the value of their product candidates with clear development and manufacturing strategies, as well as a road map to meet the appropriate quality requirements from the milligram and gram range to kilogram quantities as the product candidates move along the clinical development pathway in a cost-effective, timely, and cGMP compliant manner to enhance patients' lives. With over 20 years of experience as an independent integrated contract manufacturer, Goodwin Biotechnology has worked as a strategic partner with numerous companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established and multi-national biopharmaceutical companies. Based on the impressive track record, Goodwin Biotechnology has been awarded Frost & Sullivan's Customer Value and Leadership Award for Best Practices in Mammalian Contract Manufacturing in 2014.In addition, Goodwin Biotechnology was awarded 'Best in Sector: Biopharmaceutical Contract Development & Manufacturing' at Acquisition International magazine's 2015 Sector Performance Awards. Most recently, Goodwin Biotechnology received Global Health & Pharma's award for Best for BioProcess Development & cGMP Manufacturing in 2016, and Best in Mammalian Cell Culture Process Development & cGMP Manufacturing 2017. Click here to view the press releases!Additional information may be found at http://www.GoodwinBio.com.

Funding for this study was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number U01DA038876. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

For more information, please contact:

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-minneapolis-medical-research-foundation-selects-goodwin-biotechnology-to-help-develop-and-manufacture-two-vaccines-to-treat-opioid-addiction-300426025.html

SOURCE Goodwin Biotechnology, Inc.

http://www.goodwinbio.com

Here is the original post:
The Minneapolis Medical Research Foundation Selects Goodwin ... - PR Newswire (press release)